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Loss of the E3 ubiquitin ligase MKRN1 represses
diet-induced metabolic syndrome through AMPK
activation
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AMP-activated protein kinase (AMPK) plays a key role in controlling energy metabolism in
response to physiological and nutritional status. Although AMPK activation has been pro-
posed as a promising molecular target for treating obesity and its related comorbidities, the
use of pharmacological AMPK activators has been met with contradictory therapeutic
challenges. Here we show a regulatory mechanism for AMPK through its ubiquitination and
degradation by the E3 ubiquitin ligase makorin ring ﬁnger protein 1 (MKRN1). MKRN1
depletion promotes glucose consumption and suppresses lipid accumulation due to AMPK
stabilisation and activation. Accordingly, MKRN1-null mice show chronic AMPK activation in
both liver and adipose tissue, resulting in signiﬁcant suppression of diet-induced metabolic
syndrome. We demonstrate also its therapeutic effect by administering shRNA targeting
MKRN1 into obese mice that reverses non-alcoholic fatty liver disease. We suggest that
ubiquitin-dependent AMPK degradation represents a target therapeutic strategy for meta-
bolic disorders.
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Metabolic syndrome is associated with the risk of devel-oping a number of disorders, including type 2 diabetes(T2D), non-alcoholic fatty liver disease (NAFLD) and
cardiovascular disease, and has become a common pathological
condition due to the increased prevalence of obesity associated
with the western lifestyle1–3. The syndrome develops in response
to chronic disturbances in the balance between energy intake and
expenditure4. From a therapeutic perspective, cellular energy
expenditure (EE) has emerged as an attractive strategy for the
treatment of obesity and diabetes1. Although the molecular
mechanisms implicated in regulating the energy-wasting process
in brown fat and skeletal muscle have been identiﬁed, new and
effective drugs for the treatment of obesity that stimulate cellular
EE remain to be developed2.
AMP-activated protein kinase (AMPK), a cellular energy-
sensing enzyme, is a key regulator of metabolic syndrome and
comprises diverse heterotrimeric complexes containing a catalytic
(α1 or α2) subunit and two other regulatory subunits (β1 or β2
and γ1, γ2 or γ3)5,6. Under various conditions of energy stress
that elevate the AMP/ATP ratio, the binding of AMP to the γ
subunit maintains the enzyme in an activated state due to allos-
teric activation, which promotes phosphorylation by the
upstream kinases liver kinase B1 and calcium calmodulin-
dependent protein kinase kinase β6. Consequently, AMPK acti-
vation generates ATP to restore energy homeostasis by upregu-
lating catabolic processes and inhibiting energy-consuming
anabolic processes5–7.
AMPK, an attractive anti-obesity target for exploiting cellular
EE, integrates nutritional, hormonal and pharmacological inputs
to maintain the cellular energy balance8,9. In many genetic rodent
models, including leptin-deﬁcient (ob/ob) mice, sustained
decreases in AMPK activity accompany metabolic syndrome10,11.
AMPK activation mitigates metabolic syndrome in peripheral
tissues. AMPK activation in the liver promotes the phosphor-
ylation of acetyl-CoA carboxylase (ACC) to restrain fatty acid
synthesis5,7 and suppresses the activity of the transcription factors
sterol regulatory element-binding protein 1 (SREBP-1) and car-
bohydrate response element-binding protein (ChREBP)12–14,
which inhibit hepatic lipogenesis. AMPKα2 deﬁciency causes
hypertriglyceridemia15, whereas liver-speciﬁc AMPK activation
prevents diet-induced NAFLD in mice16. Pharmacological AMPK
activators, such as 5-aminoimidazole-4-carboxamide (AICA)
riboside, ameliorate insulin resistance in rodent models5,17,18,
although poor bioavailability limits their biological effects in vivo.
Furthermore, a lack of both AMPKβ1 and β2 in adipocytes
opposes the thermogenic responses of brown and beige fat and
intensiﬁes diet-induced NAFLD and glucose intolerance19, sup-
porting the physiological role of AMPK in lipid metabolism and
its clinical relevance. In contrast, the activation of hypothalamic
AMPK is associated with the promotion of appetite in response to
fasting and results in increased food intake and body weight20–22.
Given the role of AMPK in the maintenance of the whole-body
energy balance, it is not surprising that AMPK activation
increases the orexigenic effect related to the energy supply23.
Thus, despite a wide array of salutary effects of AMPK activation
on metabolic syndrome, the systemic effect of chronic AMPK
activation presents a unique challenge24. The identiﬁcation of a
tissue-speciﬁc AMPK regulatory mechanism would be an alter-
native strategy for the development of potent and selective AMPK
activators25,26.
Although AMPK phosphorylation is the best-delineated system
through which AMPK enzymatic activity is regulated, the
ubiquitin-proteasome system has begun to attract attention as a
possible regulatory mechanism that controls AMPK function in
energy metabolism27–29. Tripartite motif-containing 28, an E3
ubiquitin ligase, and UBE2O, an E2 ubiquitin-conjugating
enzyme, ubiquitinate and degrade AMPKα1 and α2, respec-
tively, resulting in AMPK dysfunction in cancer30,31. However, an
E3 ubiquitin ligase for AMPK that controls systemic metabolism
has yet to be reported.
As shown in this study, makorin ring ﬁnger protein 1
(MKRN1) is an E3 ubiquitin ligase for AMPK in the liver and
adipocyte tissues. AMPK activation in mice lacking MKRN1
prevents NAFLD, insulin resistance and obesity associated with a
high-fat diet (HFD). The possible curative effects of MKRN1
inhibition on hepatic steatosis and hyperglycaemia were further
observed using an adenoviral gene delivery system. Our study
provides new therapeutic opportunities for treating metabolic
syndrome by hijacking the E3 ubiquitin ligase for AMPK.
Results
MKRN1 inhibition induces AMPK-dependent catabolic
processes. The physiological role of MKRN1 has been well deli-
neated in cancer based on its ability to degrade several tumour
suppressors32–35. MKRN1 is also associated with adipocyte dif-
ferentiation in vitro36. However, the implications of MKRN1 for
systemic energy metabolism have yet to be studied. We initially
measured glucose metabolic activity in MKRN1-deﬁcient mouse
embryonic ﬁbroblasts (MEFs) to further deﬁne the metabolic
functions of MKRN1. Intriguingly, increased glucose uptake was
observed in MEFs lacking MKRN1 or HepG2 cells depleted of
MKRN1 (Fig. 1a, f and Supplementary Fig. 1a). Accordingly, we
observed increased levels of metabolites of glycolysis and
the tricarboxylic acid cycle (Fig. 1b, c) in MEFs lacking MKRN1.
The data suggest that MKRN1 depletion promotes energy pro-
duction via cellular glucose utilisation. In addition, our previous
reports indicated that MKRN1 suppression might promote
AMPKα1 and α2 phosphorylation35. Based on these observations,
we reasoned that the activation of AMPK signalling might be
involved in promoting glucose metabolism in MKRN1-null
MEFs. As expected, MKRN1 deﬁciency increased the levels of
activated AMPKα (phosphorylated at T172), which suppressed
the activity of its downstream target, acetyl coenzyme A ACC, via
phosphorylation (Fig. 1d). Additionally, MKRN1 ablation
induced an increase in AMPKα protein level without affecting
messenger RNA levels, suggesting that these events depend on
post-translational processes (Fig. 1d). Similar results were also
observed in MKRN1-depleted HepG2 and Hep3B cells following
transfection with two independent small interfering RNAs (siR-
NAs) (Fig. 1f and Supplementary Fig. 1b). In accordance with
AMPK activation under MKRN1 depletion, alterations in the
expression of genes that activate glycolysis and suppress fatty acid
synthesis were further observed (Fig. 1e)7,37,38. AMPKα ablation
completely reversed the effects of MKRN1 on glycolytic and
lipogenic gene expression (Supplementary Fig. 1c, d). The
implications of MKRN1 for the modulation of AMPK-mediated
regulation of glucose metabolism were further revealed by the
increased glucose uptake MKRN1-null MEFs, which was reversed
by AMPKα knockdown (Supplementary Fig. 1e, f). Given the
suppression of lipogenic gene expression, we further investigated
the effect of MKRN1 ablation on HepG2 cellular steatosis
induced by free fatty acids (FFAs). MKRN1 knockdown reduced
lipid accumulation in HepG2 cells, as indicated by Oil Red O
staining (Fig. 1g) and the triglyceride (TG) mass (Fig. 1h). These
effects were completely reversed upon AMPKα2 ablation (Sup-
plementary Fig. 1g). Corroborating these ﬁndings, fatty acid
oxidation (FAO) was enhanced in MEFs lacking MKRN1 or
HepG2 cells in which MKRN1 was ablated (Fig. 1i–k and Sup-
plementary. Fig. h–j). Thus, MKRN1 deﬁciency induces activa-
tion of the AMPK signalling pathway, leading to a metabolic
switch from anabolism to catabolism.
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MKRN1 acts as an E3 ubiquitin ligase for AMPKα. As MKRN1
depletion induced AMPKα stabilisation without affecting its
mRNA levels, the potential role of MKRN1 as an E3 ligase for
AMPKα was further investigated. The results of co-
immunoprecipitation analyses using overexpressed proteins
showed that both the N and C termini of MKRN1 bound to the β-
subunit-interacting domain of AMPKα (Supplementary Fig. 2a, b,
d, e). Recombinant MKRN1 directly interacted with AMPKα
(Supplementary Fig. 2c). Endogenous interactions between
AMPK and MKRN1 were further observed in MEFs (Supple-
mentary Fig. 2f). MKRN1 knockdown resulted in increased
AMPKα protein levels, without affecting AMPKβ and γ,
indicating that the α subunits are speciﬁc targets of MKRN1
(Fig. 2a). In addition to these observations, the AMPKα protein
displayed an extensively prolonged half-life in cycloheximide
(CHX)-treated MKRN1-null MEFs compared with that of the
control (Fig. 2b). Conversely, MKRN1 overexpression promoted
the degradation of the AMPKα1 and α2 proteins, but not of the β
and γ proteins (Fig. 2c). Further conﬁrming these ﬁndings,
AMPKα stabilised by MKRN1 depletion was degraded upon
overexpression of MKRN1 resistant to MKRN1-targeting siRNA
but was not affected by the expression of MKRN1 H307E, an E3
ligase-defective MKRN1 mutant32 (Supplementary Fig. 3a). Fur-
thermore, the levels of the AMPKα1 and α2 proteins were rescued
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Fig. 1 MKRN1 depletion stimulates glucose metabolism by activating AMPK signalling. Analysis of wild-type (WT) or MKRN1-knockout (MK1−/−)
littermate primary mouse embryonic ﬁbroblasts (MEFs) and HepG2 cells transduced with two independent siRNAs targeting MKRN1 (siMK1 #6 and siMK1
#7) or a control siRNA for 48 h. a Glucose consumption in MK1−/− MEFs (left) or MKRN1-depleted HepG2 cells (right) was measured based on the
absorption of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG) by the cells. b, c Intracellular levels of glycolytic and citric acid
cycle intermediates were determined by capillary electrophoresis–time-of-ﬂight mass spectrometry of the MEFs. Each bar represents the relative amount
of a metabolite for WT MEFs. G6P glucose-6-phosphate, F6P fructose-6-phosphate, F1,6-BP fructose-1,6-bisphosphate, G3P glucose-3-phosphate, 1,3-BG
1,3-bisphosphoglycerate, 3PG 3-phosphoglycerate, 2PG 2-phosphoglycerate, AcCoA acetyl-CoA, α-KG α-ketoglutarate. d, f To validate the AMPK
signalling pathway or mRNA levels of AMPKα subunits, immunoblotting or quantitative real-time PCR analysis was performed using MEFs (d) and HepG2
cells (f). Cell lysates were immunoblotted with antibodies against pAMPKα, AMPKα, pACC, ACC, MKRN1 and actin. e The mRNA levels of glycolytic or
lipogenic enzymes in MEFs were analysed by quantitative real-time PCR. g, h FFA-induced steatosis in HepG2 cells. Oil Red O staining (g) and TG levels
(scale bar= 100 µm (top), 50 µm (bottom) (h) of the cells treated with FFA/FFA-free bovine serum albumin (BSA), which served as controls. All the
experiments with MEFs were conducted in cells within the ﬁrst 3–6 passages. i Fatty acid oxidation was analysed in MKRN1-depleted HepG2 cells. j The
basal oxygen consumption rate (OCR) was measured in WT and MK1−/− MEFs. k After sequential treatment with oligomycin, FCCP and rotenone/
antimycin-A in the presence of BSA or BSA conjugated to palmitate, OCR was measured in WT orMK1−/−MEFs. The results were normalised against total
protein levels using XF-Analyze. All data are presented as the mean ± standard deviation (s.d.) of triplicate samples and are representative of at least three
independent experiments. two-tailed Student’s t-test; *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001
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Fig. 2 The E3 ubiquitin ligase MKRN1 ubiquitinates and degrades AMPKα subunits. a MKRN1 knockdown increases AMPKα1 protein levels. The
HepG2 cells were transfected with MKRN1 siRNAs (#6 and #7). b MKRN1 knockout stabilises AMPKα. WT or MK1−/− MEFs were treated with CHX
(100mgml−1) at the indicated time points. c, d MKRN1 expression promotes the proteasomal degradation of AMPKα subunits. The protein levels of
ectopically expressed AMPK subunits were analysed using HEK293T cells. GFP was used as a transfection control (c). HepG2 cells were infected with
retrovirus expressing MKRN1, followed by selection using puromycin. The cells were treated with 20 µM of MG132 for 6 h, and AMPKα1, α2, MKRN1 and
actin were detected with the indicated antibodies (d). eMKRN1 induces both AMPKα1 and α2 ubiquitination. Constructs expressing FLAG/AMPKα1, α2, β1,
γ1, 3.1/MKRN1 and HA/Ub were transfected into 293T cells. The ubiquitination assay was performed using cell lysates under denaturing conditions (in 1%
SDS buffer). f, g MKRN1 directly ubiquitinates AMPKα subunits. In vitro ubiquitination of AMPKα1 (f) and α2 (g). h, i MKRN1 is required for the
ubiquitination of AMPKα. Ubiquitinated endogenous AMPKα was determined under denaturing conditions using MG132-treated MEFs (h) and HepG2 cells
(i). All the experiments with MEFs were conducted in cells within the ﬁrst 3–6 passages. The data are representative of at least three independent
experiments
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by the addition of an MG132 proteasome inhibitor (Fig. 2d),
suggesting that MKRN1 degrades AMPKα in a proteasome-
dependent manner.
Consistent with these results, MKRN1 promoted the ubiqui-
tination of both AMPKα1 and α2 predominantly through K48-
linked polyubiquitination (Fig. 2e and Supplementary Fig. 3b, c).
In vitro ubiquitination reactions using recombinant proteins
revealed that MKRN1 directly facilitated the ubiquitination of
AMPKα1 and α2, but not of AMPKβ and γ (Fig. 2f, g and
Supplementary Fig. 3d). In contrast to wild-type (WT) MKRN1,
the enzymatically inert H307E MKRN1 mutant failed to promote
AMPK ubiquitination, despite its ability to bind to AMPK
(Fig. 2f, g and Supplementary Fig. 2b). Notably, MKRN1-null
MEFs and MKRN1-depleted HepG2 cells displayed decreased
ubiquitination of endogenous AMPKα compared with that of the
control, indicating that MKRN1 might be a pivotal E3 ligase for
AMPKα (Fig. 2h, i). Based on these results, both AMPKα1 and α2
are direct and robust targets of the MKRN1 E3 ubiquitin ligase.
MKRN1 deﬁciency reduces HFD-induced obesity. The ﬁnding
that the metabolic functions of MKRN1 are implicated in reg-
ulating AMPK activity and thus in cellular metabolic home-
ostasis, regardless of nutritional and pharmacological cues, led us
to explore the physiological roles of MKRN1 in MKRN1-null
mice, which do not exhibit apparent developmental deﬁcits or
overt phenotypes39. We ﬁrst compared the body weights of male
MKRN1-null mice to WT mice that were fed standard chow or an
HFD to elucidate any potential role of MKRN1 in fat deposition
and obesity. No differences in body weight were observed under
the standard chow feeding conditions. On the other hand,
MKRN1-null mice fed an HFD exhibited 25–30% lower body
weights than those of WT mice, without any obvious differences
in food intake (Fig. 3a–c and Supplementary Fig. 4a, b). We
observed similar results for female MKRN1-null mice compared
with WT mice under HFD conditions (Supplementary Fig. 5a–d).
Little difference was observed between MKRN1-null and WT
mice in plasma leptin levels, supporting the ﬁnding that there was
no difference in the amount of feeding (Supplementary Fig. 4c).
In addition, there were no signiﬁcant changes in gross faecal
energy, the levels of TG and FFA in faeces or bone length
(Supplementary Fig. 4d, e), suggesting that the decreased body
weights of the MKRN1-null mice were not due to changes in
nutritional excretion or morphology. Notably, micro-computed
tomography (micro-CT) revealed a reduction in the total body fat
content, including the volume of subcutaneous, visceral and
abdominal fat, and an increase in the lean mass/body weight ratio
(Fig. 3d, e). Accordingly, decreased sizes of individual adipocytes
in epididymal and subcutaneous fat pads were observed in
MKRN1-null mice (Fig. 3f, g). Consequently, HFD-induced
hyperlipidaemia was almost completely normalised in MKRN1-
null mice, which displayed similar plasma lipid concentrations to
those of WT mice fed a standard chow diet (Fig. 3h). We further
tested whether a lack of MKRN1 induces AMPK activation
in vivo, contributing to the metabolic phenotype of MKRN1-null
mice. MKRN1 is widely expressed throughout the body40,41.
Intriguingly, MKRN1-null mice exhibited chronic AMPK acti-
vation in the liver and white (WAT) and brown (BAT) adipose
tissues (Fig. 4g, Supplementary Fig. 6a–c, Supplementary Fig. 10b,
and Supplementary Fig. 11c), regardless of nutritional status.
However, no changes in AMPK activity were observed among
other metabolic organs, including the hypothalamus, skeletal
muscle and pancreas (Supplementary Fig. 6d–f). In particular, the
lack of an apparent change in hypothalamic AMPK activity and
its downstream target, pACC, strongly supported the near-equal
food intake observed in WT and MKRN1-null mice, as previously
reported23 (Supplementary Fig. 6d). Notably, there was no
obvious difference in the liver mRNA levels of MKRN1 between
mice fed normal chow and mice fed an HFD, indicating the
possible existence of pathway regulating the interaction between
MKRN1 and AMPK (Supplementary Fig. 6g). Together, these
data support the hypothesis that MKRN1 deﬁciency potentially
protects against nutrient overload-induced obesity through the
tissue-speciﬁc regulation of AMPK.
Hepatic AMPK activation prevents steatosis in MKRN1-
knockout mice. The reduction in FFA-induced hepatic steatosis
in MKRN1-ablated HepG2 cells and the chronic AMPK activa-
tion in the livers of MKRN1-null mice led us to investigate the
effect of MKRN1 deﬁciency on HFD-induced NAFLD. The lack
of MKRN1 dramatically changed the morphology (Fig. 4a), his-
tological appearance (Fig. 4b) and weight (Fig. 4c) of the fatty
liver associated with an HFD. Notably, size and morphology of
the livers from MKRN1-null mice fed an HFD were similar to
those of mice maintained on a chow diet. A substantial reduction
in the number and volume of enlarged lipid droplets was
observed inMKRN1-null mice (Fig. 4b, d). Likewise, a decrease in
the hepatic TG content was observed in MKRN1-null livers
compared with that in the WT livers (Fig. 4e). No signiﬁcant
difference in the F4/80-positive macrophage populations was
observed, indicating that immune responses did not occur
(Fig. 4f). Despite the suppression of AMPK activity under con-
ditions of nutrient overload5,10, the lack of MKRN1 caused the
remarkable stabilisation of AMPK, which was accompanied by
increases in AMPK and ACC phosphorylation (Fig. 4g).
Accordingly, the expression levels of transcription factors such as
SREBP-1 and ChREBP were suppressed in MKRN1-null livers
(Fig. 4h). Furthermore, in response to the HFD, plasma levels of
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT), which are biomarkers employed to diagnose hepatic
damage, were elevated in WT mice but were signiﬁcantly reduced
in MKRN1-null mice (Fig. 4i). There was no obvious difference in
glycogen accumulation or the generation of lactate in the liver
between MKRN1-null and WT mice, suggesting that metabolic
pathways related to lipogenesis are most strongly affected by
MKRN1 depletion in the liver (Supplementary Fig. 7). Based on
these data, MKRN1 deﬁciency promotes hepatic AMPK activa-
tion, possibly resulting in reduced hepatic lipid accumulation and
the prevention of NAFLD.
Next, AMPK activity was inhibited through adenoviral delivery
of small hairpin RNAs (shRNAs) targeting AMPKα2 to
determine the role of hepatic AMPK activation in the prevention
of hepatic steatosis in MKRN1-null mice (Fig. 4j and Supple-
mentary Fig. 8). AMPK activation in the MKRN1-null liver was
completely reversed by AMPKα2 knockdown (Supplementary
Fig. 8b). Notably, the substantial reductions in lipid droplets and
TG contents observed in the MKRN1-null liver were dramatically
restored by hepatic AMPKα2 knockdown (Fig. 4k, l), without
affecting the body weights ofMKRN1-null mice. Finally, the levels
of the lipogenesis markers SREBP-1 and ChREBP, which were
decreased in MKRN1-null mice, were restored upon AMPKα2
knockdown, corroborating the physiological data (Fig. 4m). Thus,
MKRN1 deﬁciency protects against diet-induced hepatic steatosis
in an AMPK-dependent manner.
MKRN1 ablation alters metabolism in the liver and adipocytes.
To investigate how cellular processes are inﬂuenced by MKRN1
ablation at the global level, we performed mRNA-sequencing
analysis of the liver and adipose tissues from MKRN1-null and
WT mice. Using mRNA-sequencing data, we identiﬁed 2310 (492
upregulated and 1879 downregulated) and 3383 (1379
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upregulated and 2121 downregulated) differentially expressed
genes (DEGs) between MKRN1-null and WT mice in the liver
and adipose tissues, respectively (Supplementary Data 1).
To examine how metabolic processes are affected by MKRN1
ablation, further functional enrichment analyses of the DEGs in
the liver and adipose tissue were carried out. Among different
functional categories, the DEGs were found to be most strongly
associated (41.4% in the liver and 41.5% in the adipose tissue)
with metabolism, suggesting that MKRN1 depletion signiﬁcantly
impacts metabolic processes in the liver and the adipose tissue
(Fig. 5a). Notably, lipid metabolism (41.7% in the liver and 33.9%
in the adipose tissue) was one of the processes that was most
inﬂuenced by MKRN1 ablation, together with carbohydrate
metabolism (20.9% in the liver and 24.5% in the adipose tissue)
(Fig. 5b). Among cellular processes related to lipid metabolism,
lipid anabolism pathways (i.e., lipid and fatty acid biosynthetic
processes) were signiﬁcantly (P < 0.05) downregulated in both
MKRN1-null liver and adipose tissues (Fig. 5c–f). In the liver, the
genes involved in the biosynthesis of saturated and unsaturated
fatty acids from acetyl-CoA (Acaca/b, Fasn, Tecr, Hsd17b12,
Elovl1/2/5/6/7, Scd1/2 and Acot2) were downregulated, as were
the genes involved in the conversion of glycerol to fatty acids (Gk,
Agpat4, Gpam, Lpin2, Plpp2/5, Pnpla3 and Lpl), suggesting
systematic suppression of fatty acid biosynthetic pathways by
MKRN1 ablation (Fig. 5e). In adipose tissue, similar down-
regulation of fatty acid biosynthetic pathways was observed
(Fig. 5f). On the other hand, the genes involved in lipolysis (Acsl3/
4/5 and Cpt1b) were downregulated in the liver, but those (Acsl3/
6 and Cpt1b) in the same pathway were upregulated in the
adipose tissue (Fig. 5e, f). These data suggest that MKRN1
ablation results in stricter regulation of fatty acids in the adipose
tissue by decreasing lipogenesis and increasing lipolysis with
respect to the regulation of these processes in the liver, by which
both lipolysis and lipogenesis are decreased.
In addition to lipid metabolism, carbohydrate metabolism was
signiﬁcantly inﬂuenced by MKRN1 ablation (Fig. 5b). In the liver,
the genes involved in glycolysis (Hk1/2, Gpi1, Pfkp, Aldoa, Gapdh,
Eno1, Pkm and Pklm) and gluconeogenesis (G6pc and Pck2) were
downregulated (Fig. 5e). In the adipose tissue, however, the genes
involved in glucose uptake (Slc2a4/Glu4) and glycolysis were
upregulated (Fig. 5f), as were those involved in lipolysis. On the
other hand, lactate dehydrogenase was upregulated in the adipose
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tissue (Ldha), but downregulated (Ldhb) in the liver (Fig. 5e, f).
Glucose metabolism is linked to fatty acid metabolism through
acetyl-CoA. Up- and downregulation of glucose utilisation in the
adipose tissue and the liver, respectively, reﬂect an increased
amount of acetyl-CoA and, thus, a larger supply of acetyl-CoA for
fatty acid biosynthesis in the adipose tissue than in the liver,
which might lead to the upregulation of lipolysis in the adipose
tissue (Fig. 5f). Furthermore, the genes involved in BAT
thermogenesis (Ucp1, Clic5 and Ppargc1a) were signiﬁcantly
upregulated in MKRN1-null adipose tissue (Fig. 5d). mTOR
signalling was previously shown to be one of the main targets of
AMPK42,43. Analyses of the mTOR pathway showed that mTOR
and its upstream (Hras, Mapk3, Pik3r1 and Rheb) and down-
stream (Eif4e, Sgk1, Pparg and Srebf1) genes were downregulated
in the liver, while its upstream (Pik3r1/3, Pik3cb and Akt2) and
downstream (Rps6kb2, Eif4e, Prkca/g and Pparg) genes were
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downregulated in the adipose tissue (Supplementary Fig. 9).
These ﬁndings suggest that the activation of AMPK by MKRN1
ablation negatively regulates mTOR signalling in the liver and the
adipose tissue. Taken together, these data suggest systematic
customised regulation of fatty acid and glucose metabolism in the
liver and the adipose tissue by MKRN1 and AMPK.
MKRN1 deﬁciency suppresses HFD-induced diabetes. MKRN1
depletion promoted AMPK activation in adipose tissue, in addi-
tion to hepatocytes (Fig. 4g and Supplementary Fig. 6a–c). A lack
of AMPK in adipocytes exacerbated the detrimental effects of an
HFD, including NAFLD and insulin resistance, due to reductions
in the metabolic activity of BAT19. In addition, AMPK activity in
BAT has been implicated in the regulation of uncoupling protein
1 (UCP1) induction during thermogenesis44. Therefore, we pos-
tulated that AMPK activation in adipocytes would protect against
obesity-induced BAT dysfunction45–47 and contribute to the anti-
obesity effects on MKRN1-null mice. Consistent with the body
weight results, the morphology of BAT (Supplementary Fig. 10a),
UCP1 expression (Supplementary Fig. 10b), EE and oxygen
consumption (VO2) (Supplementary Fig. 10c) did not differ
between different genotypes fed a chow diet. In contrast,
MKRN1-null mice fed an HFD showed reduced numbers of lipid
droplets in BAT (Supplementary Fig. 11a, b), along with AMPK
stabilisation and activation (Supplementary Fig. 11c) and
expression of thermogenic genes in BAT, such as UCP1 (Sup-
plementary Fig. 11c, d). Under HFD feeding conditions, the
respiratory exchange ratio of both WT and MKRN1-null mice
varied in the range of 0.7–0.8, indicating complete dependence on
fatty acid metabolism (Supplementary Fig. 11f). Contrary to our
expectations, indirect calorimetry measurements performed for
2 days showed no signiﬁcant difference in EE among genotypes
when the mice were fed an HFD (Supplementary Fig. 11g). The
overall data show that MKRN1-null mice maintain BAT activity
as a result of resistance to weight gain when fed an HFD.
AMPK activation has been implicated in the regulation of BAT
activity and hepatic gluconeogenesis, which are closely linked to
insulin resistance7,19. We observed a decrease of rate-limiting
enzymes, including glucose-6-phosphatase and phosphoenolpyr-
uvate carboxykinase, in hepatic gluconeogenesis (Fig. 5d), and an
increase in the thermogenic function of BAT and WAT in
MKRN1-null mice (Fig. 5 and Supplementary Fig. 11). Consistent
with these ﬁndings, MKRN1-null mice placed on an HFD
displayed lower fasting plasma insulin levels (Supplementary
Fig. 12a), a decrease in the HFD-induced enlargement of
pancreatic islets (Supplementary Fig. 12b), increased glucose
clearance, as indicated by glucose tolerance testing in both male
and female mice (Supplementary Fig. 12c), and greater insulin
sensitivity, as indicated by insulin tolerance testing (Supplemen-
tary Fig. 12d). Moreover, MKRN1 deﬁciency promoted insulin-
stimulated AKT phosphorylation, a signature signalling pathway
that reﬂects insulin sensitivity in the liver (Supplementary
Fig. 12e). However, these pathways were not speciﬁcally activated
in the skeletal muscle or WAT (Supplementary Fig. 12e).
Collectively, AMPK activation alleviates obesity-induced insulin
resistance and T2D in MKRN1-null mice.
An acute reduction of hepatic MKRN1 level improves NAFLD.
The metabolic consequences of chronic AMPK activation
exhibited by MKRN1-null mice led us to investigate whether
hepatic AMPK activation was sufﬁcient to improve NAFLD
without affecting the activation of AMPK in adipose tissue and
whether the acute reduction of MKRN1 expression would alle-
viate the symptoms of hepatic steatosis in obese mice. We gen-
erated adenoviruses expressing two independent shRNAs
targeting MKRN1 (Ad-shMKRN1 #1 and #2) and injected these
viruses into diet-induced obese mice via the tail vein to answer
these questions (Fig. 6a). Following the delivery of adenovirus to
mice, which was conﬁrmed by green ﬂuorescent protein (GFP)
co-expression, the adenovirus was predominantly observed in the
liver (Fig. 6b). The administration of both Ad-shMKRN1 #1 and
#2 successfully ablated MKRN1 expression and led to the acti-
vation of hepatic AMPK and ACC phosphorylation (Fig. 6c). No
apparent changes in BAT were observed (Fig. 6d). Notably, while
there was no effect on the body weight of the mice, hepatic
MKRN1 knockdown in obese mice dramatically reversed the
generation of enlarged lipid droplets and reduced TG levels in the
liver (Fig. 6e–g). In addition, the alleviation of hepatic steatosis
accompanied the salutary effects on hyperlipidaemia in Ad-
shMKRN1-injected obese mice (Fig. 6k). The decreases in
SREBP-1 and ChREBP support the reduction of lipid droplets
and hypolipidaemia observed in the liver upon MKRN1 knock-
down (Fig. 6h). On the other hand, the knockdown of MKRN1 in
the liver had no apparent effect on the adipose tissues (Fig. 6i, j).
These observations reveal that MKRN1 could be a potential
therapeutic target for alleviating the symptoms of hepatic
steatosis.
Discussion
The pharmacological and genetic activation of AMPK is asso-
ciated with a wide range of effects on whole-body metabolism,
including the suppression of gluconeogenesis and lipogenesis in
the liver, promotion of glucose consumption in the skeletal
muscle and potential functions in FAO and lipolysis in the liver
and BAT5,26,48. Thus, AMPK has been suggested as an attractive
target for the treatment of metabolic disorders. However, exten-
ded follow-up studies have presented issues and challenges
because of the complexities of chronic activation of AMPK and
AMPK-independent actions. Here the inhibition of the E3 ubi-
quitin ligase MKRN1 was sufﬁcient to chronically activate AMPK
in the liver and adipose tissues and subsequently led to systemic
effects by preventing hepatic lipid accumulation and insulin
Fig. 5 Regulation of lipid and glucose metabolism by MKRN1 and AMPK. a, b Relative proportions of DEGs in MKRN1-null liver and adipose tissues
according to their associated GOBPs. The GOBP terms at level 1 (a) and levels 2–4 (b) were used for general cellular processes and metabolic processes,
respectively. c Cellular processes related to lipid and carbohydrate metabolism enriched by the up- and downregulated genes identiﬁed inMKRN1-null liver
or adipose tissue. The bars represent −log10 (P-value), where the P-value is the signiﬁcance of the processes being enriched by the up- or downregulated
genes. d Heat maps showing the changes in the expression of DEGs involved in fatty acid biosynthesis and β-oxidation, gluconeogenesis and
thermogenesis. The colour bar shows the gradient of the log2 fold changes of mRNA expression levels in MKRN1-depleted samples relative to those in WT
samples. e, f Network models describing alterations of metabolic reactions regulated by DEGs in MKRN1-null livers (e) and adipose tissue (f). Arrows
denote metabolic reactions, and dotted lines denote the transportation of molecules or regulation involving intermediate regulators between the linked
molecules. Node colours represent up- (red) or downregulation (green) in MKRN1-null livers or adipose tissue. The colour bar represents the gradient of
the log2 fold changes of mRNA expression levels induced by MKRN1 ablation relative to those in WT
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resistance and promoting anti-obesity effects on diet-induced
obese mice. Our ﬁndings highlight a therapeutically exploitable
axis regulating AMPK, without the ramiﬁcations of activation in
central circuits.
Substantial evidence supporting the beneﬁcial effects of AMPK
activation on peripheral tissues has rapidly emerged. Chronic
treatment with direct AMPK activators, such as A76966217, PF-
73949 or AICA [5-aminoimidazole-4-carboxamide] riboside18,
restrains hepatic lipid accumulation and promotes glucose dis-
posal. In a more recent study, genetic activation of hepatic AMPK
through the γ1 mutation (γ1D316A) compellingly prevented
hepatic TG accumulation in mice placed on a high-fructose
diet16. AMPK has also been implicated in BAT functions and
energy metabolism44,50, suggesting its possible therapeutic use for
obesity. Recently, Mottillo et al.19 reported a role for adipocyte
AMPK in BAT thermogenesis, with implications for hepatic
steatosis and insulin resistance. However, in this study, diet-
induced obesity was not signiﬁcantly affected by the loss of
AMPK. Because mice placed on a long-term HFD show a
decrease in adipose AMPK activity5,10, the additional effect of
AMPK deﬁciency on obesity might not be reﬂected in these
models. Supporting this hypothesis, greater weight gain after a
relatively short-term HFD challenge has been observed in the
adipose tissue of AMPK-null mice19. The MKRN1-null mouse
displays liver- and adipose tissue-speciﬁc AMPK activation. Thus,
hepatic AMPK activation induced by MKRN1 depletion protects
the liver from lipid accumulation, while simultaneously sup-
pressing the expression of gluconeogenic genes.
Functional enrichment and network analyses revealed the
differential regulation of AMPK, mTOR and fatty acid and glu-
cose metabolism between the liver and the adipose tissue.
Although we showed that AMPKs were regulated at the protein
level by MKRN1, the mRNA expression levels of Prkaa2/
AMPKα2, Prkab2/AMPKβ2 and Prkag3/AMPKγ3 were increased
in adipose tissue by MKRN1 ablation but showed no change in
the liver, suggesting that there are additional metabolic needs to
be accommodated by the increases of AMPKs, even at the mRNA
level in adipose tissue (Supplementary Fig. 9a, b). In mTOR
signalling, the MAPK pathway (Hras, Mapk3, Pik3r1 and Rheb)
and its upstream and downstream factors (Eif4e, Sgk1, Pparg and
Srebf1) were predominantly downregulated in the liver, while the
PI3K-AKT pathway (Pik3r1/3, Pik3cb and Akt2) and its down-
stream factors (Rps6kb2, Eif4e, Prkca/g and Pparg) were pre-
dominantly downregulated in the adipose tissue (Supplementary
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Fig. 6 Ablation of hepatic MKRN1 improves hepatic steatosis in diet-induced obese mice. a Male B6 mice (6 weeks old) were fed an HFD for 9 weeks and
then injected with either PBS or adenoviruses expressing GFP via the tail vein (Ad_control, Ad_shMK1 #1 and #2 (shRNA targeting MKRN1)). After 1 week
of continuous HFD feeding, the mice were sacriﬁced and analysed. b Immunoblot analysis of GFP expression in extracts from the indicated tissues (Sub
subcutaneous fat, Epi epididymal fat) of mice infected with adenovirus (n= 2). c, d Liver (e) and BAT (d) lysates from adenovirus-injected mice were
analysed by immunoblotting as indicated. e Body weights of male mice fed with an HFD were measured in every 2 days for 8 days (n= 5 mice per group).
f Representative H&E staining of liver sections. Scale bar= 50, 100 and 500 µm. g Liver TG levels were measured. h Lipogenic enzymes were analysed via
quantitative real-time PCR (n= 5 mice per group). i Representative H&E staining of epididymal fat (top) and subcutaneous fat (bottom) sections. Scale
bar= 500 µm. j The weights of fat tissues were recorded following sacriﬁce. k Liver TG levels (n= 5 mice per group). Plasma lipid (TG, cholesterol and
FFA) concentrations in 24-h-fasted mice (n= 5 mice per group). The data are presented as the mean ± s.d. Two-tailed Student’s t-test; *P≤ 0.05,
**P≤ 0.01, ***P≤ 0.001.
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Fig. 9a, b). Although Pparα is one of the major transcription
factors involved in lipid metabolism, there was no apparent
change in the expression of Pparα in the liver or adipose tissue.
We cannot, however, exclude the possibility that MKRN1 reg-
ulates Pparα at the post-translational level, since Pparγ is known
to be a target of MKRN136. Further studies are required to
address this issue in the future. Although genes related to lipo-
genesis was consistently downregulated in both the liver and the
adipose tissue, the catabolism of fatty acids and glucose was
upregulated in the adipose tissue but downregulated in the liver,
indicating the differential regulation of metabolic pathways in
MKRN1-null mice (Fig. 5e, f). Importantly, further experiments
including direct measurements of the lipid components in the
liver should be carried out to reach explicit conclusions about the
reduction of actual biochemical outcomes derived from com-
prehensive changes of the lipogenic genes. Of note most of the
phenotypes observed in the MKRN1-null mouse could also be
driven by AMPK-mediated phosphorylation of ACC, which
suppresses its function. Thus, we cannot exclude the possibility
that this process might have considerable negative effects on the
accumulation of lipids in MKRN1-null mice, in addition to the
downregulation of lipogenic gene expression. Taken together, the
differential regulation of the above processes by MKRN1 might be
ascribed to additional metabolic needs arising from the increased
uptake and utilisation of glucose in adipose tissue.
Collectively, our ﬁndings illuminate a previously undescribed
post-translation mechanism in which AMPK activity is regulated
by E3 ubiquitin ligase and provides an attractive therapeutic
strategy for the treatment of obesity and its related comorbidities.
Because MKRN1 is able to degrade both of α subunits, a com-
petitive antagonist capable of interfering with the interactions
between AMPKα and MKRN1 or an enzyme inhibitor targeting
ubiquitin ligase activity may lead to potent AMPK activation in
an organ-speciﬁc manner. This strategy may represent an effec-
tive means of ameliorating diet-induced obesity and insulin
resistance by exploiting not only hepatic AMPK activation and its
subsequent contributions to de novo lipogenesis but also adipose
AMPK activation, leading to an increase in the energy-burning
capacity of BAT.
Methods
Mice. MKRN1-null (MKRN1−/−) mice were obtained from T. A. Gray (David
Axelrod Institute, USA)39 and were further backcrossed with C57BL/6 mice until
N10. MKRN1-null mice and their WT littermates (MKRN1+/+) were bred from
MKRN1+/− mice and were randomly grouped for all the experiments. The primers
employed for MKRN1 genotyping were 5′-TGA CAGGCCACAGTGAACTC-3′,
5′- GGCAAAGCTGCTTCTTTGTCTCC-3′ and 5′-CAA AGGGAAAGGGTAAA
GTGGTAGGG-3′, which ampliﬁed an approximately 1000-bp DNA fragment in
MKRN1−/− mice and an 820-bp DNA fragment in MKRN1+/+ mice. For HFD-
induced obesity experiments, male and female MKRN1+/+ and MKRN1−/− mice
were placed on either an HFD (60% calories from fat; D12492, Research DIET Inc.,
NJ, USA) or a standard chow diet (17% calories from fat; 38057, Cargill Agri
Purina Inc., Republic of Korea) for 16 weeks starting at 6–8 weeks of age. For
adenovirus experiments, male C57BL/6 mice (6 weeks old) were placed in indi-
vidual cages, treated with an HFD for 9 weeks and injected with adenovirus via the
tail vein. After 1 week of continuous HFD feeding, the mice were sacriﬁced. All the
mice were maintained under temperature-controlled and light-controlled (standard
12-h light–dark cycles) conditions and provided with food and water ad libitum.
All the procedures were reviewed and approved by the Institutional Animal Care
and Use Committees (IACUC) of the Laboratory Animal Research Center at
Yonsei University (IACUC-A-201506-311-01).
Cell lines and transfection. MKRN1+/− mice with FBV/NJ × C57BL/6J back-
ground were backcrossed with the B6 background mice until N6. MKRN1+/− mice
were mated to produce MEFs with or without MKRN1. To acquire MEFs of 13.5
embryo day, embryos washed with phosphate-buffered saline (PBS; Welgene) were
minced followed by incubation with the treatment of 3 ml trypsin/EDTA (Gibco)
at 37 °C for 15 min. The MEFs were grown in 20 ml Dulbecco’s modiﬁed Eagle
medium (DMEM) containing 10% foetal bovine serum (FBS; GIBCO) for 4–8 h
followed by the change of media with DMEM containing 10% FBS. The conﬂuent
MEFs were then subcultured at 1:3 ratio33. HEK293T (a human embryonic kidney
cell line) and HepG2 (a human hepatocellular carcinoma cell line) cells were
acquired from the American Type Culture Collection (ATCC, Manassas, VA). The
phenotypes of these cell lines were authenticated by ATCC on a regular basis. All
the cell lines employed here were negative for mycoplasma when detected using an
e-Myco plus Mycoplasma PCR Detection Kit (Intron, Gyeonggi-do, Republic of
Korea) and were protected from mycoplasma infection by treatment with Plas-
mocinTM (InvivoGen, CA, USA). Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA), PEI (Sigma-Aldrich, St. Louis, MO, USA) or Lipofectamine RNAiMAX
(Invitrogen) were employed to transfect plasmid DNA or siRNA.
Reagents. Phospho-AMPKα (1:1000, Thr 172) (2535), AMPKα (1:1000, 2603),
AMPKα1 (1:1000, 2795), AMPKα2 (1:1000, 2757), AMPKβ1 (1:1000, 4178),
AMPKγ1 (1:1000, 4187), phospho-ACC (1:1000, 3661), ACC (1:1000, 3676),
phospho-AKT (1:1000, Ser 473) (9271) and AKT1 (1:2000, 2967) antibodies were
acquired from Cell Signaling Technology (Danvers, MA, USA). The UCP1 anti-
body (1:1000, ab10983) and mouse AMPKα1 (1:1000, ab3759) were procured from
Abcam (Cambridge, MA, USA). Mouse AMPKα2 (1:1000, AF2850) was purchased
from R&D systems Inc. (MN, USA). FLAG (1:3000, F3165 and F7425) and β-actin
(1:10000, A5316) antibodies were procured from Sigma-Aldrich. The MKRN1
antibody (1:3000, A300-990A) was procured from Bethyl Laboratories. The mono-
and polyubiquitin chain antibodies (1:1000, FK2, Biomol, PW0150) were pur-
chased from Enzo Life Sciences. The HA antibody (1:3000, 12013819001) was
obtained from Roche. GAPDH (1:5000, sc-25778), GFP (1:5000, sc-8334) and
HA (hemagglutinin) (1:3000, sc-7392 and sc-805) antibodies were procured from
Santa Cruz Biotechnology (Dallas, TX, USA). MG132 (M-1157) was purchased
from A.G. Scientiﬁc (CA, USA). CHX (C4859) was purchased from Sigma-Aldrich.
Indirect calorimetry. Metabolic performance (energy intake and EE) was studied
using a PHENOMASTER automated combined indirect calorimetry system (TSE
System GmBH, Bad Homburg, Germany). For the experiment, the mice ﬁrst
acclimated for 48 h in a metabolic chamber provided with food and water were
subsequently evaluated for 3 days for oxygen consumption (VO2), carbon dioxide
production (VCO2) and food consumption. The temperature for these studies was
kept at 22 °C, with a 12-h-light/dark cycle. Standard in-house software was used for
EE.
Micro-positron emission tomography/-CT image acquisition and analysis.
After 6 h of fasting, each mouse was intravenously injected with 200 µCi of F-18
ﬂuorodeoxyglucose via the tail vein and then maintained in a box at 4 °C for 1 h.
Each mouse was anaesthetised during the scan with isoﬂurane (2.5% ﬂow rate). The
animals were placed in a prone position on a standard mouse bed. The limbs of the
mice were positioned laterally from the body to obtain uniform CT images. Whole-
body CT images were obtained employing a micro-positron emission tomography
(PET)/-CT scanner (nanoScan PET/CT, Mediso Inc., Budapest, Hungary). The X-
ray source was ﬁxed at 200 µA and 45 kVp with 0.5 mm for CT image acquisition.
The CT images were recreated through cone beam reconstruction using a Shepp
ﬁlter with a cutoff at the Nyquist frequency and a binning factor of 4, which
resulted in an image matrix of 480 × 480 × 632 with a voxel size of 125 µm. The
PET images were recreated using the Tear-Tomo Real 3D PET engine (nanoScan
PET/CT, Mediso Inc.). The weight of each mouse was determined before taking
image of lean body mass (LBM). The overall body image, including total and
visceral adipose tissue volume was measured as reported previously51. The LBM is
deﬁned as the weight of the body without the weight of fat. Here LBM was analysed
according to the following equation, where the density of fat was 0.9 g cm−3.
Detailed methods are described in a previous report51.
LBM ¼ fbody weight gð Þ  ðtotal adipose tissue volume ðcm3Þ ´ 0:9 ðg cm3ÞÞg
ð1Þ
Glucose tolerance test (GTT), insulin tolerance test (ITT) and insulin sti-
mulation. The mice were treated with an HFD for 16 weeks and tested after an
overnight (16-h) fast. The glucose tolerance test (GTT) was performed via oral
glucose (G8769, Sigma-Aldrich) administration at a dose of 1 g kg−1 after an
overnight fast. The blood glucose levels were analysed at 0, 15, 30, 60 and 120 min
post-injection using GlucoDr. Plus (AGM-3000, Allmedicus). For insulin tolerance
test assays insulin (I9278, Sigma-Aldrich) stimulation was accomplished via
intraperitoneal insulin injection at a dose of 0.75 U kg−1 (ﬁnal volume 125 μl) after
an overnight fast. Glucose levels were measured at 0, 15, 30, 60, 90 and 150 min
after injection. Protein samples of skeletal muscle, liver and epididymal fat pads
were collected 10 min after injection for western blot analysis.
Faecal energy content. Faeces were collected and dried in a drying oven until the
samples were completely free of water. The energy contents of 0.5–1 g of dried
samples were measured using a bomb calorimeter (Parr6400 Calorimeter, IL,
USA). TG and fatty acid contents were measured using enzymatic methods
(AU680, Beckman Coulter, USA).
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Metabolomic analysis. Metabolomic analysis was performed employing the Basic
Scan package from Human Metabolome Technologies (HMT) Inc. (Tsuruoka,
Japan) and capillary electrophoresis–time-of-ﬂight mass spectrometry (CE-
TOFMS) as described previously52. Metabolites were extracted from MKRN1−/−
MEFs and the MEFs of WT littermates as the manufacturer suggested (E-130637;
HMT). Brieﬂy, the cells were washed twice using a 5% (w/w) mannitol solution,
added to methanol to extract metabolites and treated with internal standards
solution 1 (HMT). The extracted solution was centrifuged for 5 min at 2300 × g and
4 °C. The proteins of the upper aqueous layer were removed using a Millipore 5-
kDa cutoff ﬁlter. The ﬁltrate was subsequently lyophilised and dissolved in 50 µl of
Milli-Q water and analysed via CE-TOFMS. Automatic integration software
(MasterHands ver. 2.16.0.15 developed at Keio University) was employed to pro-
cess peaks from CE-TOFMS analysis and to acquire information of m/z, migration
time (MT) and a relative peak area. The HMT metabolite database based on the
peak MTs andm/z values established using TOFMS were employed to assign all the
target metabolite.
Glucose consumption measurements. HepG2 cells and MEFs were cultured in
fresh high-glucose (4500 mg l−1) medium for 24 or 48 h at 24 h after siRNA
transfection. Live cells were treated with 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino]-2-deoxy-D-glucose for 30 min (20 μM), and glucose uptake was measured
by quantifying ﬂuorescence using ﬂow cytometry.
FFA-induced steatosis. For the FFA stock solution, oleic acid (OA, 100 mM) was
conjugated with 1% (w/v) bovine serum albumin (BSA). The required volume of
the FFA stock was added to the medium to obtain a 0.5 or 1 mM concentration of
fatty acids for experiments. HepG2 cells were treated with OA complexed with BSA
or fatty acid-free BSA (as the control) for 24 h and then stained with ORO (Oil Red
O staining) . Images were procured using aNikon eclipse 80i light microscope
(Nikon, Tokyo, Japan) and analysed with Nikon NIS-Elements F 3.2 software.
Cellular TGs were also extracted from FFA-treated HepG2 cells and measured.
TG measurement. For TG measurement, 0.2-g liver samples from maleMKRN1+/+
andMKRN1−/−mice or FFA-treated HepG2 cells were homogenised in 5% NP-40 in
water, and the samples were then heated to 95 °C and cooled to room temperature
twice. TG contents were analysed using the Triglyceride Quantiﬁcation Colorimetric
Kit (Bio Vision, CA, USA). TG levels were calculated from measurements of the
absorbance at 570 nM.
FAO measurement. For FAO measurement in HepG2 cells, the cells were plated
in triplicate in 96-well plates at a density 6 × 104 cells per well. The culture medium
was changed to glucose deprivation medium (1 mM of glucose, 1 mM of L-gluta-
mine, 0.5 mM of L-carnitine, 1% FBS, penicillin/streptomycin solution, pH 7.4)
overnight, followed by replacement of the medium with FA/FA-free measurement
medium (ab217602) with or without carbonyl cyanide p-triﬂuoro-methox-
yphenylhydrazone (FCCP) in the presence of an O2 consumption reagent
(ab197243). Measurements were performed using a ﬂuorescent plate reader
(GloMAX-Discover, Promega). For FAO measurement in MEFs, an extracellular
ﬂux (XF24) analyser (Seahorse Bioscience) was used to measure oxygen con-
sumption rates (OCR). The MEFs were plated at a density of 6 × 104 cells per well
in triplicate in custom-designed 24-well plates (Cat. No. 103010-100). OCR was
evaluated over time with or without the addition of oligomycin (2.5 μM), followed
by the addition of FCCP (1.6 µM), and rotenone/antimycin-A (0.5 μM) with or
without palmitate-conjugated BSA (Cat. No. 102720-100).
Lactate measurement. The L-Lactate Assay Kit II (1200051002, Eton Bioscience)
was employed to quantitate the amount of lactate.
Serum biochemistry. Fasting plasma insulin levels were measured in mice fasted
for 16 h using the Mouse Metabolic Hormone Magnetic Bead Panel (Metabolism
Multiplex Assay, MMHMAG-44K, Millipore). Plasma TG, cholesterol and FFA
concentrations were determined using enzymatic methods (Roche Diagnostics,
Mannheim, Germany) with a Hitachi 7600 clinical chemistry analyser (Hitachi
Ltd., Tokyo, Japan) in overnight-fasted mice. Serum AST and ALT levels were
measured via ultraviolet methods (Roche Diagnostics) with a Hitachi 7600 ana-
lyser, according to the recommended protocols from the International Federation
of Clinical Chemistry.
Histology and immunohistochemistry. Tissues ﬁxed in 10% buffered formalin
were embedded in parafﬁn followed by staining with haematoxylin and eosin or
periodic acid Schiff for glycogen detection. Images were obtained using a Leica
DM2500 microscope (Leica Microsystems, IL, USA) and analysed with Leica LAS
V4.7 software. For immunohistochemistry, the ImmPRESS Peroxidase Polymer kit
(Vector Laboratories, Burlingame, CA, USA) was employed. Brieﬂy, the slides
blocked with 2.5% horse serum were incubated overnight at 4 °C with the F4/80
antibody (1:200; sc-377009; Santa Cruz Biotechnology) followed by washing. Slides
were then incubated for 30 min with an appropriate peroxidase polymer-linked
secondary antibody. For colorimetric detection the slides were stained with
ImmPact DAB substrate (SK-4105, Vector Laboratories) followed by counter-
staining with Meyer’s haematoxylin for 10 s. For Oil Red O staining, formalin-ﬁxed
tissues were equilibrated in 30% sucrose, embedded in OCT compound and snap-
frozen in liquid nitrogen. Frozen sections were stained with Oil Red O (Sigma-
Aldrich). Images were obtained using a Nikon eclipse 80i microscope and analysed
with Nikon NIS-Elements F 3.2 software. The freehand area selection tool in
ImageJ were employed to determine adipocyte size (mean area of white adipose
cells, minimum n= 3 samples per group and n= 3 ﬁelds per section).
Ubiquitination assay. The ubiquitination assay was conducted under denaturing
conditions to detect ubiquitinated endogenous and overexpressed AMPKα proteins.
Brieﬂy, to detect proteins ubiquitinated with HA-conjugated ubiquitin or endogen-
ously ubiquitinated proteins under denaturing conditions, cells were lysed by boiling
for 10min in PBS containing 1% SDS and 5mM NEM (N-ethylmaleimide). The
lysates were immunoprecipitated in lysis buffer (a ﬁnal concentration of 0.1% SDS).
For immunoblotting, proteins were transferred to polyvinylidene diﬂuoride mem-
branes and denatured using 6M guanidine-HCl containing 20mM Tris-HCl (pH
7.5), 5 mM mercaptoethanol and 1mM phenylmethyl sulphonyl ﬂuoride for 30min
at 4 °C. Ubiquitinated proteins were identiﬁed by horseradish peroxidase-conjugated
anti-Ub antibodies (FK2, PW0150, Biomol)35. For in vitro ubiquitination assays, a
0.5-µg sample of bacterially puriﬁed recombinant proteins was incubated with 100 ng
of E1 (UBE1, E-305, Boston Biochem, Cambridge, MA, USA), 250 ng of E2 (UbcH5c,
E2-627, Boston Biochem) and 5 µg of ubiquitin (U-100H, Boston Biochem) in 20 µl of
reaction buffer (40mM of Tris, 50mM of NaCl, 5mM of MgCl2, 2 mM of ATP and
1mM of dithiothreitol, pH 7.6) as indicated. The reaction was stopped after 3 h at
37 °C by the addition of SDS sample buffer and boiling.
Protein puriﬁcation and immunoprecipitation. Glutathione S-transferase (GST)-
tagged recombinant MKRN1 and the AMPKα1, α2, β1 and γ1 proteins were
puriﬁed from bacteria using GST Sepharose beads according to the manufacturer’s
protocol (GE Healthcare).
Immunoprecipitation assay: The cells were lysed in lysis buffer (50 mM of Tris-
HCl (pH 7.5), 150 mM of NaCl, 0.5% Triton X-100 and 1 mM of EDTA)
containing a protease inhibitor cocktail. The cell lysates were then incubated with
1 µg of antibody with rotation, followed by incubation with 25 µl of protein G
agarose (Invitrogen), and the precipitated proteins were eluted in SDS sample
buffer under boiling conditions53.
Recombinant adenoviruses. The adenoviral clone pAV-U6-GFP (control vector,
Ad_control) and an adenoviral clone containing an shRNA for murine MKRN1
(Ad_shMKRN1) were purchased from ViGene Biosciences Inc. (Rockville, MD,
USA). The adenoviruses were propagated in HEK293 cells according to the manu-
facturer’s protocol. Adenoviruses expressing a nonspeciﬁc RNAi control (Ad_US) and
shRNA for murine AMPKα2 (Ad_shα2) were generated via homologous recombi-
nation between the adenovirus backbone vector pAD-Easy and the linearised transfer
vector pADTrack. For animal experiments, the viruses were puriﬁed in a CsCl gra-
dient, dialysed against PBS buffer containing 10% glycerol and stored at −80 °C. The
mice were tail vein-injected with the recombinant adenovirus (0.5 × 109 pfu per mice).
Plasma ALT and AST levels were not signiﬁcantly different between the mice in the
same experimental groups that were injected with various adenoviruses. The shRNA
sequences were as follows: Ad_shMKRN1 #1: 5′-CCGGGCGAGATGTTGCTTAT
GCTTTCTCGAGAAAGCATAAGCAACATCTCGC TTTTTG-3′; Ad_shMKRN1
#2: 5′-CCGGGAGTGGGACTTGTTTCACGATCTCGAGATC GTGAAACAAGT
CCCACTCTTTTTG-3′; and Ad_shα2: 5′-CCATAAAGTGGCAGTTAAG ATCTT
AAA-3′.
Statistical analysis. All statistical tests were two sided, and the values are
expressed as the means with 95% conﬁdence intervals. The normality of the dis-
tribution was assessed with the Kolmogorov–Smirnov method. Statistically sig-
niﬁcant differences between any two groups were examined using unpaired two-
tailed t-tests or Mann-Whitney U tests, depending on normality. Data involving
more than two groups were assessed via analysis of variance using GraphPad Prism
software (version 7; GraphPad Software Inc., La Jolla, CA). Analysis of covariance
(ANCOVA) was employed to compare genotypes, with adjustment for the con-
founding effect of mouse body weight for EE. The EE ANCOVA method used in
this work was provided by the NIDDK Mouse Metabolic Phenotyping Centers
(MMPC, www.mmpc.org) on their Energy Expenditure Analysis page (http://www.
mmpc.org/shared/regression.aspx) and supported by grants DK076169 and
DK115255. A value of P < 0.05 was considered statistically signiﬁcant.
mRNA-sequencing and data analysis. Total RNAs were obtained from the liver
and adipose tissues of MKRN1-null and WT mice. Poly(A) mRNA isolation from
total RNA and fragmentation was performed using the Illumina TruSeq RNA
Sample Prep Kit v2, according to the manufacturer’s instructions. Reverse tran-
scription of RNA fragments was performed using Superscript II reverse tran-
scriptase (Life Technologies). The adaptor-ligated libraries were sequenced on the
Illumina HiSeq 4000 platform (Marcrogen, Korea). mRNA-sequencing analysis
was performed with two independent replicates from each condition. Adapter
sequences (TruSeq universal and indexed adapters) were removed from the
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resulting read sequences for each sample using cutadapter software54. Then, the
remaining reads were aligned to the mouse GRCh38 genome using
Tophat2 software (version 2.1.1) with the default parameters55. After alignment, we
computed RPKM (reads per kilobase of target per million mapped reads) for the
gene features (GTF ﬁle of GRCm38.91) using Cufﬂinks56.
Identiﬁcation of DEGs. The numbers of reads counted by HTseq were converted
to log2 read counts after adding one to the read counts. The log2 read counts for the
samples from each condition were then normalised via the trimmed mean of M-
values normalisation in the edgeR package57. To identify DEGs, we performed
integrative statistical hypothesis tests as previously described58. Brieﬂy, for each
gene, we calculated a T-statistic value using Student’s t-test as well as the log2 fold
change in the comparison of MKRN1-null versus WT. We then estimated the
empirical distributions of T-statistic values and the log2-fold-change for the null
hypothesis (i.e., the genes are not differentially expressed) by performing all pos-
sible combinations of random permutations of the four samples. Using the esti-
mated empirical distributions, we computed adjusted P-values for the two tests for
each gene and then combined these P-values using Stouffer’s method59. Finally, we
identiﬁed DEGs as those genes showing combined P-values ≤ 0.05 and absolute
log2 fold changes ≥ 0.58 (1.5-fold). To identify the cellular processes represented by
the DEGs, we performed enrichment analysis of gene ontology biological processes
(GOBPs) using DAVID software60 and selected the GOBPs with P-values < 0.05 as
the processes enriched by the DEGs.
Reconstruction of a network model. To construct a network model for the DEGs,
we ﬁrst selected a subset of the DEGs involved in the GOBPs related to mTOR
signalling (Supplementary Fig. 9a, b) and glucose and fatty acid metabolism (Fig. 5c).
We then collected the protein–protein interactions for these genes from ﬁve inter-
actome databases: Biomolecular Interaction Network Database, Human Protein
Reference Database, Biological General Repository for Interaction Datasets, Molecular
INTeraction Database and Search Tool for Recurring Instances of Neighbouring
Genes61–65. The initial network model was built with the target genes and their
interactors using Cytoscape66. We then arranged the nodes according to their asso-
ciated GOBPs and Kyoto Encyclopedia of Genes and Genomes pathways67 related to
glucose and fatty acid metabolism, such that the nodes involved in the same GOBPs
and pathways were located close to each other.
Data availability. Uncropped gels and blots are available in the Supplementary
Information (Supplementary Figs. 13–22).
RNA-seq data generated for this study have been deposited in the Gene
Expression Omnibus database under accession number GSE115012.
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